Zoetis has announced the launch of Versican Plus Bb Oral, a vaccine against Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC).Zoetis has announced the launch of Versican Plus Bb Oral, a vaccine against Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC).

Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.

Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.

"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."

Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.

Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.

"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."

Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.

Whilst you're here, take a moment to see our latest job opportunities for vet nurses.